Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Celgene Quarterly Profit Falls on High Research Expenses

Celgene Corp., maker of the cancer drug Revlimid, said first-quarter earnings fell 27 percent on higher costs for research and development.

Net income fell 27 percent to $279.7 million, or 66 cents a share, from $384.9 million, or 89 cents, a year earlier, the Summit, New Jersey-based company said in a statement today. Earnings excluding one-time items were $1.67 a share, beating by 2 cents the average of 27 analysts’ estimates compiled by Bloomberg.

Expenses for R&D increased 8.5 percent to $358 million in the quarter, due to “an increase in clinical trial activity for pipeline assets,” Celgene said in the statement. Trials are continuing for lung cancer drug Abraxane and psoriatic arthritis treatment Otezla.

Revenue increased 18 percent to $1.73 billion, as sales of Revlimid, approved by the U.S. Food and Drug Administration in June 2013 for use in mantle cell lymphoma, gained 14 percent to $1.14 billion. Revlimid sales missed analysts’ average estimate of $1.17 billion. Celgene is now submitting Revlimid for treatment of newly diagnosed multiple myeloma patients in the U.S. and in Europe, the drugmaker said today.

Celgene also said today it bought a late-stage product for Crohn’s disease from Nogra Pharma Limited, a closely-held pharmaceutical company based in Dublin, Ireland. Nogra will receive an upfront payment of $710 million. Celgene plans to initiate a final-stage registration program for Crohn’s disease, an inflammatory bowel disorder, by the end of the year, according to the statement.

Celgene fell 2.5 percent to close at $141.25 in New York. The company has gained 19 percent in the past 12 months.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.